Brimapitide
- Generic Name
- Brimapitide
- Drug Type
- Small Molecule
- Chemical Formula
- C164H286N66O40
- CAS Number
- 1445179-97-4
- Unique Ingredient Identifier
- 2K30142185
- Background
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 309
- Registration Number
- NCT02508337
- Locations
- 🇺🇸
Ora, Andover, Massachusetts, United States
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 339
- Registration Number
- NCT02235272
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Xigen SA
- Target Recruit Count
- 24
- Registration Number
- NCT01570205
- Locations
- 🇨🇭
Covance Clinical Research, Allschwil, BS, Switzerland
Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Auris Medical AG
- Target Recruit Count
- 210
- Registration Number
- NCT00802425
- Locations
- 🇩🇪
LMU Munich Klinikum Grosshadern, Munich, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath